期刊文献+

丙型肝炎病毒型特异性聚合酶链反应基因分型的临床应用 被引量:4

下载PDF
导出
摘要 目的 探索丙型肝炎病毒 (HCV)基因型在不同人群中的分布规律及流行优势型。方法 分别对健康体检者、住院患者和血液透析患者抗HCVIgG阳性标本 ,用自行设计的 5’非编码区 (5’ NCR) 1、2、3、1b型特异性引物进行扩增和基因分型。结果  3组人群中血液透析患者HCV感染率最高 ,抗HCVIgG和HCVRNA阳性率分别为 5 5 .37%和 38.84%。基因型以 1b亚型为主 ,1b及 1b的相关型占 91.6 7%。结论 本地区HCV流行优势型为 1b亚型。
出处 《上海医学检验杂志》 北大核心 2003年第6期388-390,共3页 Shanghai Journal of Medical Laboratory Sciences
基金 江苏省社会发展资助课题 (编号 :BS990 31)
  • 相关文献

参考文献9

  • 1张道强,邓新心,蒋赐恩,隋秀梅.血液透析及肾移植患者乙型和丙型肝炎病毒感染状况分析[J].中华医院感染学杂志,1997,7(1):30-31. 被引量:12
  • 2张建琼,李丽,林陵,张雪萍,韩光明,单祥年.5’-非编码区型特异性引物检测HCV基因型[J].上海医学检验杂志,2000,15(4):195-196. 被引量:6
  • 3Khau RU, Tong CYW, Bloom S, et al. Evaluation of two simplified methods for genotyping hepatitis C virus[J]. J Med Viol.1997,52:35.
  • 4Alter H J, Purcell R H, Shih J W, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A non-B hepatitis[J]. N Engl J Med, 1990,321 : 1492.
  • 5Okuda K, Hayashi H, Yokozeki K, et al. Mode of nosocomial HCV infection among chronic hemodialysis patients and its prevention [ J ]. Hepatology, 1994,19:293-298.
  • 6Sampietro M, Badalamenti S, Salvadori S, et al.High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV [ J ]. Kidney Int,1995,47.911-917.
  • 7Stuyver L, Claeys H, Wyseur A, et al. Hepatitis C virus in a hemodialysis unit: molecular evidence for nosocomial transmission [J]. Kidney Int, 1996, 49:889-895.
  • 8Okamoto H, Sugiyarna Y, Okada S, et al. Tying hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infection sources[J]. J Gen Virol, 1992,73 : 673-684.
  • 9Sampietro M, Badalamenti S, Salvadori S, et al.High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV [J ]. Kidney Int,1995,47:911-917.

二级参考文献5

共引文献16

同被引文献17

  • 1唐文红,韦毅,胡刚.红面猴(Macaca arctoides)B病毒的检疫研究[J].广西师范大学学报(自然科学版),1997,15(1):87-90. 被引量:8
  • 2Kobayashi M, Chayama K, Arase Y, et al. Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6 [J]. J Gastroenterol, 1999, 34(4):505-509.
  • 3Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States[J]. N Engl J Med, 1999, 341(8) :556-562.
  • 4Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial[J]. Lancet, 2001, 358(9286) :958-965.
  • 5Carithers RL, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials[J]. Hepatology, 1997, 26(3 Suppl 1) :83S-88S.
  • 6Wills RJ. Clinical pharmacokinetics of interferons [J]. Clin Pharmacokinet, 1990, 19(5):390-399.
  • 7Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy[J].Science, 1998, 282(5386):103-107.
  • 8Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C [J]. N Engl J Med, 2000, 343(23) :1666-1672.
  • 9Waizmann M,Ackermann G,et al. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin[J]. J Subst Abuse Treat,2010,38(4) : 338-345.
  • 10Bressler B,Wang K,Grippo J. F,etal. Pharmacokinetlcs and response of obese patients with chronic hepatitis C treated with dif- ferent doses of PEG-IFN alpha-2a (40KD) (PEGASYS)[J]. Br J Clin Pharmacol, 2009,67 (3) : 280-287.

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部